Baergic Bio, Inc. Fortress Biotech Partner Company
BAERGIC BIO 2
Forward Looking Statements
This presentation may contain “forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include, but are not limited to, any statements relating to our growth strategy and product
development programs and any other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are subject to risks and uncertainties
that could negatively affect our business, operating results, financial condition and stock price. Factors
that could cause actual results to differ materially from those currently anticipated include: risks relating to
our growth strategy; government regulation; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development
activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and
completing clinical trials; our dependence on third-party suppliers; our ability to attract, integrate, and
retain key personnel; the early stage of products under development; our need for substantial additional
funds; patent and intellectual property matters; competition; as well as other risks described in the SEC
filings of Fortress Biotech, Inc. We expressly disclaim any obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances on which any such statement is
based, except as required by law.
BAERGIC BIO 3
BAER-101 Overview
1. Licensed from AstraZeneca, BAER-101 (formerly
known as AZD7325), is a high affinity, selective
modulator of GABAα receptor system
2. Selective positive allosteric modulator (PAM) for
GABAα2/3, minimizing adverse events that are
typically seen with benzodiazepines, which are non-
selective agonists
3. Established safety profile well tolerated in early
clinical trials (over 500 patients)
GABA(α) Importance of Selectivity
BAERGIC BIO 4
Alpha 1 = Sedating effects/tolerance
Alpha 2 = anxiolytic/anti-convulsant
Alpha 3 = anxiolytic/anti-convulsant
Alpha 5 = cognitive dulling
GABA(α) Subtypes
Non-selective agonist at alpha 1, 2, 3, 5
Benzodiazepines
Selective agonist at alpha 2, 3
BAER-101
BAERGIC BIO 5
Addressable Market: Refractory Epilepsy
BAER-101 will target areas of unmet need where chronic use
of a selective GABAα PAM is impactful, including Refractory
Epilepsy
Refractory Epilepsy
Epilepsy is among the most prevalent neurological disorders, affecting ~1%
of the world population (~3mm in the US)
~30% of patients are not adequately controlled by standard of care
A significant factor behind refractory patients is non-compliance as result of
significant side effects from non-specific drugs
BAER-101’s unique drug profile can potentially provide an alternative
treatment option for this significant unmet need
Finalization of pre-clinical proof-of-concept data for BAER-101 to
support IND in Refractory Epilepsy anticipated in 2H 2021